First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Humanization of an anti-p185HER2 antibody for human cancer therapy.

1992 • 1,867 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells

1987 • 1,015 citations

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 • 1,013 citations

Treatment of Breast Cancer

1998 • 790 citations

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1992 • 769 citations

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1999 • 687 citations

Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells

1987 • 657 citations

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

1987 • 627 citations

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1993 • 501 citations

The addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase II trial.

1998 • 366 citations

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells

1997 • 344 citations

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

1999 • 296 citations

Herceptin<sup>®</sup> Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials

2001 • 179 citations

Retrospective Analysis of the Safety of Herceptin<sup>®</sup> Immunotherapy in Metastatic Breast Cancer

2001 • 156 citations

Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?

1999 • 133 citations